Recent News

• 08.06.2025 - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 08.05.2025 - Neuronetics Reports Second Quarter 2025 Financial and Operating Results
• 08.04.2025 - Neuronetics to Present at the Canaccord Genuity 45th Annual Growth Conference
• 07.30.2025 - NeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents
• 07.22.2025 - Neuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call
• 07.15.2025 - Neuronetics Appoints New Chief Financial Officer
• 06.19.2025 - Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 06.10.2025 - Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook’s Personalized Care Trial Program
• 06.02.2025 - Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

Recent Filings

• 08.06.2025 - 424B5 Prospectus [Rule 424(b)(5)]
• 08.05.2025 - EX-99.1 EX-99.1
• 08.05.2025 - 8-K Current report
• 08.05.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.18.2025 - EFFECT Notice of Effectiveness
• 07.15.2025 - 3 Initial statement of beneficial ownership of securities
• 07.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.15.2025 - 8-K Current report
• 07.15.2025 - EX-99.1 EX-99.1
• 07.03.2025 - S-3 Registration statement under Securities Act of 1933